More top stories
PROSTRAKAN shares hit a record high yesterday after the group announced its largest-ever drug outlicensing deal, earning it an immediate $10 million (£6.2m) payment, writes Hamish Rutherford.
PROSTRAKAN, the fast-growing Borders pharmaceutical company, is establishing an office in Italy, the largest European market in which it does not yet have its own sales force.
PROSTRAKAN has continued its march towards profitability, revealing a 40 per cent rise in sales in the first half of the year.
SCOTTISH drugs company ProStrakan is expected to declare this week that it is just a few months from breaking into the black for the first time.
PROSTRAKAN has settled a long-running dispute with one of its largest shareholders, after agreeing to pay 9.15 million (£7.8m) towards a tax liability incured by Aventis.
PROSTRAKAN is increasingly confident of hitting monthly break-even this year after being given early clearance to launch a cancer pain drug in France.
PROSTRAKEN has poached Allan Watson, the chief financial officer of Optos.
STRONG early sales of two key cancer treatments saw ProStrakan yesterday report a 40 per cent rise in sales in the first four months of the year.
PROSTRAKAN has filed a review of its testosterone gel with the US Food and Drug Administration, six years after the organisation deemed the treatment not approvable.
PROSTRAKAN, the Borders-based pharmaceutical company, has continued to build a revenue stream from its first US-approved drug, announcing two deals for its anti-nausea patch, Sancuso.
THE chief executive of one of Scotland's specialist drug companies has predicted that its latest hormone-based product will win approval from US regulators.
PROSTRAKAN has been approached for mergers from cash-strapped biotech companies from both sides of the Atlantic as the industry suffers from a major low in investor confidence.
PROSTRAKAN, the Borders pharmaceutical company, has been boosted by a positive drug trial for its treatment for cancer-related pain, which it plans to launch next year.
PROSTRAKAN, the Borders pharmaceutical company, has been given a $55 million (£27.1m) boost for its launch into the United States.
PROSTRAKAN, the Borders-based pharmaceutical specialist, has begun recruiting for final stage trials in the US for a drug tipped to make it millions, and potentially alleviate excruciating pain, writes Hamish Rutherford.
A NEW treatment to help minimise some of the side-effects of chemotherapy could be set to net a Scottish pharmaceutical firm up to £3 million.
Borders pharmaceutical company ProStrakan has signed a licensing deal in South Korea for Sancuso, its anti-nausea treatment for chemotherapy patients.
PROSTRAKAN has entered a joint venture to expand its operations throughout the Nordic region.